BaEV retrovirus vector packaging method and packaging cell line thereof

By expressing gag-pol protein and knocking out ASCT-1/2 receptors in HEK293T cells, and combining this with horizontal centrifugation transduction technology, a stable BaEV retrovirus packaging cell line was constructed. This solved the problems of low NK cell transduction efficiency and high production cost, and achieved efficient and stable viral vector preparation and NK cell transduction.

CN119020418AActive Publication Date: 2024-11-26SHENZHEN CELL VALLEY BIOMEDICAL CO LTD

Patent Information

Application Number
CN202411135840.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-17
Publication Date
2024-11-26
Estimated Expiration
2044-08-17

AI Technical Summary

Technical Problem

In existing technologies, NK cell transduction efficiency is low, making it difficult to achieve efficient and stable viral transduction. Furthermore, existing retroviral vectors have high production costs, making large-scale application difficult.

Method used

A stable BaEV retrovirus packaging cell line was constructed by expressing gag-pol protein and knocking out ASCT-1/2 receptors in HEK293T cells, combined with horizontal centrifugation transduction technology to improve the transduction efficiency and stability of the viral vector.

Benefits of technology

It achieves efficient and stable NK cell transduction, reduces virus preparation costs, simplifies the production process, and is suitable for large-scale industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020418A_ABST
    Figure CN119020418A_ABST
Patent Text Reader

Abstract

The invention provides a packaging method of a BaEV retrovirus vector, which comprises the following steps: constructing a BaEV retrovirus stable packaging cell line, transfecting a virus preparation cell line with a retrovirus vector plasmid comprising a target sequence, and harvesting a retrovirus vector for transient conversion toxin production by using the virus preparation cell line which is an HEK293T cell line or a derivative cell line thereof, and mixing with a BaEV retrovirus stable packaging cell line, and promoting the transduction of the BaEV retrovirus stable packaging cell line by the retrovirus vector in a horizontal centrifugation manner. According to the invention, packaging of the BAEV type retrovirus vector carrying the CD19CAR exogenous gene plasmid can be realized, a BAEV type retrovirus vector production cell line is constructed, and the high-titer BAEV type retrovirus vector is produced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of cell therapy, and in particular to a packaging method of a BaEV retroviral vector and a packaging cell line thereof. Background Art

[0002] At present, the development of CAR-T and CAR-NK products faces the following challenges in terms of underlying technology: low transduction efficiency, poor amplification multiples, and poor cryopreservation. Among them, efficient transduction of NK cells is the bottleneck of CAR-NK development. As a natural immune barrier, NK cells are naturally resistant to infection and are not easily transduced by viruses. Currently, lentiviral vectors are commonly used on the market to transduce NK cells, and lentiviral vectors are usually encapsulated with VSVG (vesicular stomatitis virus envelope glycoprotein). Although the receptor low-density lipoprotein (LDL) of the VSVG envelope is expressed in large quantities on activated T cells, it is less expressed on activated NK cells. At present, the use of mature VSV-G-encapsulated lentiviruses is not enough to solve the above-mentioned transduction and genetic manipulation problems. A large number of studies have shown that the efficiency of VSV-G lentivirus transduction of NK cells is extremely low (only 5-10%), and the reason for this phenomenon is most likely because NK cells have natural antiviral ability. In response to the problem of low efficiency of VSVG enveloped lentiviral vector transduction of NK, some studies have used small molecule inhibitors to upregulate the expression of LDL-R (low-density lipoprotein receptor) on the surface of NK cells to increase the transduction efficiency of VSVG enveloped lentivirus, and some studies have used BX795 to inhibit NK antiviral signals to increase NK transduction efficiency, but they all face the disadvantages of unstable CAR positivity, high toxicity that is not conducive to CAR-NK cell expansion, and inability to be applied in clinical practice on a large scale and stably. In particular, BX795 will have a certain impact on the killing function and proliferation ability of NK cells, which obviously does not meet the requirements of clinical application. Some studies have also shown that some retroviruses can efficiently transduce NK cells, but there are certain risks in the safety of retroviral insertion sites.

[0003] Patent WO2013 / 045639A1 discloses that a modified lentivirus (BaEV lentivirus) packaged with baboon endogenous retrovirus (BaEV) envelope glycoprotein can efficiently transduce T cells and B cells. Although BaEV envelope glycoprotein (BaEV-G) has extremely high application value, it is difficult to produce high-titer pseudoviral particles from BaEV envelope glycoprotein. CN117467705 A discloses an efficient BaEV envelope virus packaging method, which includes introducing BaEV envelope glycoprotein or a vector containing BaEV envelope glycoprotein encoding nucleic acid, target gene encoding nucleic acid and viral packaging elements into target cells; or constructing a cell line that stably expresses BaEV envelope glycoprotein, and introducing target gene encoding nucleic acid and viral packaging elements into the cell line.

[0004] In order to improve the transduction efficiency of NK cells, the most common method currently is to use other envelope proteins to construct lentiviral vectors. Studies have shown that baboon endogenous retrovirus (BaEV) envelope glycoprotein pseudotyped lentiviral vector (BaEV-LV) can significantly improve the transduction efficiency of NK cells, and its transduction efficiency is better than that of VSVG-LV vector.

[0005] At present, most BaEV enveloped lentiviral vectors and BaEV enveloped retroviral vectors can only produce pseudoviruses by transiently transfecting expression plasmids and packaging plasmids into HEK293T cells, which is inefficient and has problems such as DNA residues, resulting in cumbersome subsequent purification processes and unstable virus titers and virus quality between batches. This method of transient transfection to prepare BaEV pseudoviruses cannot produce high-quality pseudoviruses in large quantities and stably, and is difficult to apply on a large scale, resulting in high initial R&D and industrialization costs for pseudovirus preparation.

[0006] Currently, the BaEV envelope glycoprotein used for lentivirus packaging mainly has the following forms: 1. Wild-type BaEV-WT; 2. BaEV-Rless, that is, the BaEV envelope glycoprotein form without fusion restrictive R peptide; 3. BaEV / TR, that is, the BaEV envelope glycoprotein form in which the wild-type BaEV-WT cell tail domain is replaced with the MLV envelope glycoprotein cell tail domain. Compared with BaEV-Rless, the BaEV / TR form has greatly reduced cytotoxicity and greatly reduces the appearance of syncytia during virus packaging, but the virus titer is lower than that of the BaEV-Rless form. It is reported that BaEV-Rless can improve the transduction efficiency of primary cells compared with wild-type BaEV-WT. The specific forms of "BaEV-RLess" and "BaEV / TR" are described in detail in Chinese patent CN104080917B.

[0007] Currently, there is a PG13 stable packaging retroviral cell line on the market, which can produce retroviral vectors in large quantities and stably, and the viral envelope is GALV (Gibbon Ape Leukemia Virus). The GALV retroviral vector prepared by this system can achieve a transduction efficiency of more than 60% for T cells, but the transduction efficiency for NK cells is only about 20% and is limited by the size and structural complexity of the target gene. Therefore, it cannot fully meet the requirements of the field of cell therapy for efficient transduction of other difficult-to-transduce primary immune cells such as T cells and NK cells. Summary of the invention

[0008] In order to solve the above problems, the present invention provides a packaging method of a BaEV retroviral vector, which comprises the following steps: Step 1: constructing a BaEV retroviral stable packaging cell line; Step 2: transfecting a retroviral vector plasmid including a target sequence into a virus preparation cell line, wherein the virus preparation cell line is a HEK293T cell line or a derived cell line thereof, to harvest a transiently transfected toxin-producing retroviral vector; and Step 3: mixing the retroviral vector obtained in Step 2 with the BaEV retroviral stable packaging cell line obtained in Step 1, and promoting the transduction of the BaEV retroviral stable packaging cell line by the retroviral vector by horizontal centrifugation.

[0009] In one embodiment, step 1 comprises the following steps:

[0010] Step 11: Transform the structural protein gag-pol protein required for the preparation of retrovirus into HEK293T cell line or its derivative cell line to obtain the corresponding cell line containing the structural protein gag-pol protein;

[0011] Step 12: Based on the cell line obtained in step 11, a HEK293T cell line or a cell line derived therefrom in which both ASCT-1 and ASCT-2 receptor proteins are knocked out is constructed to obtain a cell line in which both ASCT-1 and ASCT-2 receptor proteins are knocked out accordingly;

[0012] Step 13: Transfer the BaEV envelope into the cell line obtained in step 12 to obtain the BaEV retrovirus stable packaging cell line.

[0013] In one embodiment, step 11 includes:

[0014] Step 111, transfecting HEK293T cell line or its derivative cell line with gag-pol plasmid;

[0015] Step 112, after transfection, adding antibiotics to screen HEK293T cell lines or cell lines derived therefrom that highly express the gag-pol target gene;

[0016] Step 113, digesting the HEK293T cell line or its derivative cell line obtained in step 112, culturing the digested cells, and selecting monoclonal cells;

[0017] Step 114, performing transient toxin production titer test on the monoclonal cells obtained in step 113, screening monoclonal cells with high toxin production titer, and obtaining the corresponding cell line containing the structural protein gag-pol protein.

[0018] In one embodiment, the step 12 comprises: step 121, knocking out the ASCT-1 gene in the cells containing the structural protein gag-pol protein obtained in step 11; step 122, flow sorting and culturing the cells obtained in step 121 to obtain monoclonal cells; step 123, selecting the monoclonal cells obtained in step 122, performing target detection, and obtaining monoclonal cells with homozygous knockout of the ASCT-1 gene; and step 124, knocking out two exons of the ASCT-2 gene in the monoclonal cells obtained in step 123, and further selecting monoclonal cells to obtain cells with knockout of ASCT-1 and ASCT-2 receptor proteins.

[0019] In one embodiment, the step 13 includes: step 131, transfecting the ASCT-1 and ASCT-2 receptor protein knockout cells obtained in step 12 with the BaEV envelope plasmid; step 132, after transfection, adding antibiotics to screen for retroviral vector packaging cell lines that highly express the BaEV envelope; step 133, digesting the BaEV enveloped retroviral vector packaging cell lines obtained in step 132, culturing the digested cells, and selecting monoclonal cells; and step 134, performing a transient toxin production titer test on the monoclonal cells obtained in step 133, screening monoclonal cells with high toxin production titers, and obtaining the BaEV retrovirus stable packaging cell line.

[0020] In one embodiment, in step 131, the BaEV envelope plasmid is a wild-type BaEV envelope plasmid or a BaEV-Rless envelope plasmid.

[0021] In one embodiment, the reverse transcription vector plasmid comprising the target sequence in step 2 is a pMFG-CD19 CAR plasmid, and the virus preparation cell in step 2 is a Phoenix-Ampho cell.

[0022] In one embodiment, after the pMFG-CD19 CAR plasmid is transfected into the Phoenix-Ampho cells and the transfected Phoenix-Ampho cells are cultured for 48-96 hours with replacement of the medium, the cell culture supernatant and Phoenix-Ampho cells are harvested to harvest the transiently transfected toxin-producing retroviral vector of step 2.

[0023] In one embodiment, in step 3, when horizontal centrifugation is used to promote the transduction of the retroviral vector into the BaEV retroviral stable packaging cell line, the retroviral vector obtained in step 2 is first mixed with the BaEV retroviral stable packaging cell line obtained in step 1 for a first centrifugal transduction and incubation to obtain the first transduced BaEV retroviral stable packaging cell line; then the retroviral vector obtained in step 2 and the first transduced BaEV retroviral stable packaging cell line are subjected to a second centrifugal transduction and incubation to finally obtain the BaEV retroviral stable packaging cell line in step 3.

[0024] In one embodiment, the temperature of the first centrifugal transduction or the second centrifugal transduction is 32° C., the centrifugal transduction time is 1 to 2 hours, and the post-transduction incubation time is 2 to 3 hours.

[0025] In one embodiment, a BaEV retrovirus stable packaging cell line prepared by the above packaging method is provided.

[0026] The present invention is the first to transfer the structural protein gag-pol and BaEV envelope protein required for the preparation of retrovirus into HEK293T cells to enable their stable expression.

[0027] The present invention knocks out the ASCT-1 / 2 receptors of HEK293T cells for the first time, which solves the problem of cell-cell fusion and syncytium formation induced by BaEV envelope, allowing cells to produce toxins normally; on the other hand, it avoids repeated infection of BaEV virus itself and causes cell death. After knocking out ASCT1 / 2 receptors, cells are no longer affected by viral infection, can continue to grow, and continue to produce toxins.

[0028] The present invention develops a stable packaging cell line (BaEV-PackRV) that can stably and mass-produce BaEV retroviral vectors. This packaging cell line has provided retroviral gag, pol and envelope proteins (BaEV) to mediate the packaging and transcription of the target gene. First, the plasmid containing the target gene is transiently transfected into a common virus preparation cell line, such as the HEK293T cell line or its derivative cell line, such as Phoenix-Ampho, etc., and the supernatant is collected to transduce BaEV-PackRV, thereby obtaining a stable virus-producing production cell line. Therefore, only a small amount of plasmid is used for the production of retroviral vectors in the first step of transient transfection, which saves a large number of plasmid preparation and purification processes. For subsequent virus preparation, it is only necessary to resuscitate the toxin-producing cell line and collect the cell culture supernatant, which is the required retroviral vector. Using the BaEV stable packaging cell line as the production raw material for retroviral vectors greatly reduces the cost of virus preparation; reducing impurities and downstream purification processes, the cost of virus preparation for cell therapy products is reduced by more than 10 times.

[0029] The present invention determines the best method for preparing BAEV-type retroviral production cell lines based on the exploration of the positive rate of BaEV-PackRV cells transduced by transiently harvested retroviral vectors based on different combinations of transient virus harvesting time and temperature, centrifugation time and incubation time. The method can realize the packaging of BAEV-type retroviral vectors carrying CD19 CAR exogenous gene plasmids, construct BAEV-type retroviral vector production cell lines, and produce high-titer BAEV-type retroviral vectors.

[0030] In addition, the expression level of envelope receptors on NK cells is correlated with the efficiency of viral integration. The BaEV envelope receptors are neutral amino acid transporters ASCT-1 and ASCT-2 (ASCT-1 / 2), both of which are highly expressed on activated NK cells, facilitating efficient viral infection of NK cells and thus improving the transduction efficiency of NK cells.

[0031] The present invention prepares a BaEV retrovirus stable packaging cell line (BaEV-PackRV) for low-cost, high-quality and efficient large-scale industrial preparation of pseudoviruses and their application in efficient transduction of cell therapy products. Compared with the transiently transfected BaEV lentivirus, high-titer virus vectors can be produced without multi-plasmid transfection, the production process is simpler, the cost is lower, the product quality can be better controlled and large-scale production can be carried out; compared with the GALV retrovirus that can be stably packaged, efficient transduction of difficult-to-transduce primary immune cells such as NK cells and T cells can be achieved at a lower multiplicity of infection (MOI), the transduction positive rate can be as high as 90% and maintained stable, and the ultra-high transduction efficiency does not affect the viability and amplification of NK cells and T cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0033] Figure 1 is a flowchart of the construction of BaEV retrovirus packaging cells of the present invention;

[0034] Figure 2 This is the result of RT-PCR detection of the relative expression level of gag-pol in HEK293T-gag-pol monoclonal cells;

[0035] Figure 3This is the flow cytometry graph of HEK293T-gag-pol monoclonal cell toxin titer detection;

[0036] Figure 4 It was identified by sequencing of HEK293T-gag-pol-ASCT-1-KO homozygous knockout monoclonal cells, and 8 ASCT-1 gene knockout homozygous cells were screened;

[0037] Figure 5 This is the result of Western blot verification of the expression of ASCT-1 gene in homozygous knockout monoclonal cells;

[0038] Figure 6 This is the result diagram of sequencing verification of ASCT-2 receptor knockout;

[0039] Figure 7 This is the result of PCR detection of exon knockout in HEK293T-gag-pol-ASCT-1-KO monoclonal cells;

[0040] Figure 8 The BaEV envelope plasmid was transfected into HEK293T-gag-pol-ASCT-1&2-KO and HEK293T cells respectively, and the growth status of the two cells was recorded by taking photos under a microscope 24 hours later;

[0041] Fig. 9 This is the result of RT-PCR detection of BaEV envelope copy number of BaEV-expressing monoclonal cells after transfection of BaEV envelope plasmid into HEK293T-gag-pol-ASCT-1&2-KO cells;

[0042] Fig.10 The cells with a high copy number of BaEV envelope were selected and counted every two days to draw a growth curve.

[0043] Fig.11 This is the flow cytometry graph of the transient toxin production titer detection of BaEV-Rless-57 and BaEV-WT-64;

[0044] Fig.12 This is a graph showing the transduction positive rate results of the BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP toxin-producing cell lines detected by flow cytometry;

[0045] Fig.13 This is the result of the transduction positive rate of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP stable transfection toxin production titer

[0046] Fig.14This is the result graph of the positive rate of GALV-CD19 CAR and BaEV-CD19 CAR transduced T cells;

[0047] Fig.15 It is the CAR-T cell proliferation fold curve;

[0048] Fig.16 This is the result graph of the positive rate of NK cells transduced by GALV-CD19 CAR and BaEV-CD19 CAR;

[0049] Fig.17 It is a CAR-NK cell proliferation multiple curve. DETAILED DESCRIPTION

[0050] In order to enable those skilled in the art to better understand the technical solutions in this application, the present invention will be further described below in conjunction with embodiments. Obviously, the described embodiments are only part of the embodiments of this application, rather than all of the embodiments. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of this application.

[0051] Cell sources: HEK293T, Phoenix-Ampho, Phoenix-ECO, and PG13 cells are all commercial cell lines purchased from ATCC. Plasmid sources: pCMV-MMLV-gag-pol-PGK-puro, pMFG-CD19 CAR, pMFG-copGFP, pCMV-BaEV-Rless-PGK-hygr-PA, pCMV-BaEV-WT-PGK-hygr-PA, and PX458 plasmids are all commercial plasmids purchased from Guangdong Junhou Biopharmaceutical Co., Ltd. The reagents and raw materials used in the present invention are all from commercial reagents unless otherwise specified.

[0052] The present invention provides a method for constructing a BaEV retrovirus packaging cell line. Figure 1 The specific method is described as follows.

[0053] Example 1 Construction and screening of HEK293T-gag-pol cells

[0054] 1. HEK293T cell recovery and plating

[0055] HEK293T cells were revived in DMEM containing 10% FBS and cultured in a 5% CO2 cell culture incubator for 48 h. When the cell confluence reached about 80%, the cells were digested and 8×10 5 The cells were seeded in 6-well plates and cultured in a 37°C, 5% CO2 incubator.

[0056] 2. pCMV-MMLV-gag-pol-PGK-puro plasmid transfection

[0057] After 24 hours of HEK293T cell plating, the cell confluence was observed under a microscope to reach 70-80%, and then transfection was performed. Prepare the transfection system: 3.3 μg of pCMV-MMLV-gag-pol-PGK-puro plasmid, 3:1 ratio of FugeneHD:DNA, and DMEM medium to 200 μL. After mixing, let stand at room temperature for 15 minutes, add 200 μL to each well, and culture in a 37°C, 5% CO2 incubator.

[0058] 3. Puromycin screening:

[0059] 24 hours after transfection, the medium was replaced with DMEM complete medium containing 3 μg / mL puromycin, and the cells were treated every two days. After the medium was changed, the screening concentration of puromycin was maintained at 3 μg / mL. After one week of drug screening, the cells were treated every four days, and after the medium was changed, puromycin was used for screening at a final concentration of 8 μg / mL to obtain HEK293T-gag-pol cells that highly expressed the gag-pol target gene.

[0060] 4. Select monoclonal cells:

[0061] HEK293T-gag-pol cells were digested, the cell density was adjusted to 100 cells / mL, and the cells were inoculated into 96-well plates. 100uL of cell suspension was added to each well, and the cells were cultured in a 37°C, 5% CO2 incubator. The cell growth status was monitored, and the monoclonal cells were gradually expanded.

[0062] 5. Monoclonal cell identification:

[0063] Extract RNA from monoclonal cells and reversely obtain cDNA, and perform RT-PCR to detect the expression of gag-pol ( Figure 2 ). The gag-pol primers were gag-pol-qPCR-F: gacggaaatggtggaga; gag-pol-qPCR-R: atgcctgcgaggtagtg.

[0064] Figure 2 It shows the gag-pol gene expression levels of different monoclonal cells, but it cannot represent the gag-pol protein expression level and protein function. Therefore, we selected 6 monoclonal cell lines with high expression (clone 2), medium expression (clone 10, clone 19, clone 28), and low expression (clone 1, clone 14) of gag-pol gene for transient transfection and toxin production test.

[0065] 6. Toxin production by HEK293T-gag-pol monoclonal cells:

[0066] The above 6 monoclonal cells were selected for transient transfection and toxin production test. The transfection method was the same as above. Prepare the transfection system: the amount of pMFG-copGFP plasmid was 1μg, the amount of pCMV-BaEV-Rless-PGK-hygr-PA or pCMV-BaEV-WT-PGK-hygr-PA plasmid was 500ng respectively, and the DMEM medium was filled to 100μL. After 24h of transfection, fresh DMEM complete medium was replaced and placed in a 32℃ incubator for toxin production. After 48h, the cell supernatants were collected respectively, and the cell supernatants were filtered with a 0.45μm filter membrane for titer detection.

[0067] 7. Detection of toxin titer produced by transient transfection of HEK293T-gag-pol monoclonal cells:

[0068] HEK293T cells were seeded in 24-well plates at 2 × 10 5 After 24 hours, discard the cell culture medium, add 1mL of the virus solution to be tested, then add 1μg / mL polybrene, centrifuge at 32℃2500rpm for 1h. Continue to culture in a 37℃ incubator. After 24 hours of viral transduction, replace with fresh culture medium. After 48 hours, flow cytometry is used to detect the transduction efficiency ( Figure 3 ). Calculation method of virus biological titer: virus titer (TU / mL) = number of cells infected * percentage of positive cells / volume of virus stock solution (Table 1). Flow cytometry detected the infection positive rate of retrovirus produced by HEK293T-gag-pol monoclonal cells transiently transformed into HEK293T cells at different dilution ratios, which reflects the biological titer of the virus.

[0069] Transient transfection and toxin production tests were performed on the 6 selected HEK293T-gag-pol monoclonal cells, among which HEK293T-gag-pol-Clone 1 had a higher toxin production titer. Subsequently, Clone 1 cells will be selected for KO cell line construction.

[0070] Table 1: Detection of toxin titer of different HEK293T-gag-pol monoclonal cells

[0071] Transduction positive rate Virus titer (TU / mL) Clone 1 62.8% 1.54E+06 Clone 2 8.38% 2.05E+05 Clone 10 9.69% 2.37E+05 Clone 14 6.71% 1.64E+05 Clone 19 15.8% 3.87E+05 Clone 28 44.8% 1.10E+06

[0072] Example 2 Construction of HEK293T-gag-pol-ASCT-1&2-KO cell line

[0073] 1. Plasmid construction:

[0074] Design ASCT-1-gRNA and ASCT-2-gRNA fragments, and synthesize primers. For specific primers, see Table 2. The target fragment is formed by self-ligation of primers. The PX458 plasmid is double-digested with BbsI restriction endonuclease and recovered and purified. The target fragment and the linearized vector are seamlessly cloned, and the product is transformed into DH5α Escherichia coli, shaken and plated for overnight culture, and single clones are picked for shaking, sequencing and double enzyme digestion verification.

[0075] Table 2 Primer sequences

[0076] Primer name Primer sequences ASCT-1-gRNA-F CACCAACAACGTAGAGCTCAACGC(SEQ ID NO.1) ASCT-1-gRNA-R AAACGCGTTGAGCTCTACACTGTT(SEQ ID NO.2) ASCT-2-gRNA-1-F CACCAAACCCCTACCGCTTCCTGT(SEQ ID NO.3) ASCT-2-gRNA-1-R AAACACAGGAAGTAGTAGGGGTTT(SEQ ID NO.4) ASCT-2-gRNA-2-F CACCGAGGAATATCACCGGAACCA(SEQ ID NO.5) ASCT-2-gRNA-2-R AAACTGGTTGCGGTGATATTCCTC(SEQ ID NO.6)

[0077] 2. HEK293T-gag-pol knockout of ASCT-1 gene:

[0078] Add 3 μg of PX458-ASCT-1-gRNA plasmid to 150 μl of electroporation buffer to prepare electroporation reaction solution. 6 HEK293T-gag-pol-Clone 1 was centrifuged and the supernatant was discarded. After adding the electroporation reaction solution, it was gently blown and transferred to the electroporation cup. The electroporation was performed using the Lonza 2b electroporator with the electroporation program Q-001. After the end, the cell suspension in the electroporation cup was aspirated and added to the preheated DMEM medium for continued culture. The PX458-ASCT-1-gRNA plasmid was GFP-tagged and transiently expressed after electroporation of HEK293T-gag-pol-Clone 1. GFP-positive cells were sorted by flow cytometry after 24 hours.

[0079] 3. Select monoclonal cells:

[0080] Adjust the density of flow-sorted GFP cells to 100 cells / mL, inoculate them into 96-well plates, add 100uL of cell suspension to each well, and culture the cells in a 37°C, 5% CO2 incubator. Monitor the cell growth status, gradually expand the monoclonal cells, and expand and verify them after the cells are fully grown.

[0081] 4. Targeting detection of HEK293T-gag-pol-ASCT-1-KO monoclonal cells:

[0082] DNA of monoclonal cells was extracted and PCR was performed to detect the expression of ASCT-1 gene. The primers of ASCT-1 were ASCT-1-F: ggtctgagacaagacacatg; ASCT-1-R: gtcactctaagggatggcag. The PCR products were sequenced and the results were compared with the website https: / / decodr.org / . Sequencing revealed 8 homozygous knockout clones ( Figure 4). HEK293T-gag-pol-ASCT-1-KO homozygous knockout monoclonal cells were sequenced and identified, and 8 homozygous ASCT-1 gene knockout cells were screened. Eight homozygous knockout clones were selected for Western blot verification of ASCT-1 gene expression. Figure 5 Western blot results showed that the ASCT1 gene was not expressed in HEK293T-gag-pol-ASCT-1-KO-Clone-30 cells, so Clone-30 was selected to knock out the ASCT-2 gene.

[0083] 5. HEK293T-gag-pol-ASCT-1-KO knockout of ASCT-2 gene:

[0084] HEK293T-gag-pol-ASCT-1-KO-Clone-30 cells were electroporated with PX458-ASCT-2-gRNA-1 plasmid and PX458-ASCT-2-gRNA-2 plasmid to knock out the two exons of the ASCT-2 gene, and further monoclonal cells were selected using the same method as before. The genome of the monoclonal cells was extracted and sequenced using 1-ASCT-2-F. In order to ensure that all transcripts of the ASCT-2 protein were destroyed, 8 clones with deletion fragments greater than 5000 bp were screened, and Clone-30, 47, 51, and 58 were selected for the next PCR verification experiment. See Table 3 for PCR detection primers for ASCT-2.

[0085] According to the PCR results in the figure, the PCR results of the three pairs of primers of the HEK293T-gag-pol-ASCT-1-KO-Clone-47 clone were all negative, indicating that the ASCT-2 gene knockout of the Clone-47 monoclonal cell was successful, so Clone-47 was selected for the next experiment. Sequencing verified the knockout of the ASCT-2 receptor, such as Figure 6 As shown, the genome of monoclonal cells was extracted and sequenced to verify the knockout of ASCT-2 receptor. A total of 8 HEK293T-gag-pol-ASCT-1-KO monoclonal cells with deletion fragments greater than 5000 were screened. The Western blot results are shown in Figure 7 As shown, three pairs of primers were used to detect the knockout of two exons of the ASCT02 gene. The PCR test results showed that all transcripts of the ASCT-2 protein in Clone-47 single cells were destroyed.

[0086] Table 3 PCR primers for ASCT-2

[0087]

[0088] Example 3 Construction of BaEV stable packaging cell line

[0089] 1. Transfection of BaEV envelope plasmid into HEK293T-gag-pol-ASCT-1&2-KO cells:

[0090] The above HEK293T-gag-pol-ASCT-1&2-KO-clone-47 cells were seeded in a six-well plate. After 24 hours of cell plating, the cell confluence was observed under a microscope to reach 70-80%. pCMV-BaEV-Rless-PGK-hygr-PA and pCMV-BaEV-WT-PGK-hygr-PA were transfected into HEK293T-gag-pol-ASCT-1&2-KO cells respectively. Prepare the transfection system: the amount of plasmid was 3.3μg, the ratio of Fugene HD: DNA was 3:1, and the DMEM medium was filled to 200μL. After mixing, let it stand at room temperature for 15 minutes, add 200μL to each well, and culture it in a 37℃, 5% CO2 incubator.

[0091] 24h after transfection, the growth status of the two cells was recorded by microscope. Figure 8 ). After transfection, the cell status of HEK293T-ASCT-1&2-KO cells was significantly better than that of wild-type HEK293T cells. After knocking out the ASCT-1 and ASCT-2 genes, the problem of syncytia formation after BaEV transfection and inability to produce toxins normally was solved.

[0092] 2. Hygromycin screening:

[0093] 24 hours after transfection, the medium was replaced with DMEM complete medium containing 3 μg / mL hygromycin, and the cells were treated every two days. After the medium was changed, the hygromycin screening concentration was maintained at 300 μg / mL. After one week of drug screening, the cells were treated every four days, and after the medium was changed, puromycin was used for screening at a final concentration of 800 μg / mL to obtain a retroviral vector packaging cell line that highly expressed the BaEV-WT or BaEV-Rless target gene.

[0094] 3. Picking single clones:

[0095] Digest the cells selected by hygromycin, adjust the cell density to 100 cells / mL, inoculate into 96-well plates, add 100uL of cell suspension to each well, and culture the cells in a 37°C, 5% CO2 incubator. Monitor the cell growth status, gradually expand the monoclonal cells and freeze them.

[0096] 4. Detection of BaEV envelope copy number in monoclonal cells:

[0097] Single-cell RNA was extracted and reversed to obtain cDNA, and RT-PCR was performed to detect the expression of BaEV-Rless or BaEV-WT envelope. The primers for BaEV envelope detection were BaEV-qPCR-F: ggcatacacttatctacccacgaac; BaEV-qPCR-R: tgatcaatagcagggatggggac. Prepare the RT-PCR reaction system according to Table 3. Pipette 15 μL of the mixed solution into 8 consecutive PCR reaction wells, with 3 replicate wells in each group. See Table 4 for the reaction system, and set the fluorescent PCR amplification program according to Table 5. In addition, the BaEV plasmid was used as a positive quality control, and its copy number was calculated: (6.02×10 23 times copy number / mole)×(ng / μL×10 9 ) / (DNA length × 660) = copies / μL, and a standard curve was drawn. According to the standard curve, the number of BaEV envelope copies of each monoclonal cell was calculated ( Fig. 9 ).

[0098] Fig. 9 The copy number levels of BaEV envelope in different monoclonal cells are shown. In BaEV-Rless cells, the R57 (BaEV-Rless-57) monoclonal envelope expression level is the highest; in BaEV-WT cells, the W64 (BaEV-WT-64) monoclonal envelope expression level is the highest.

[0099] Table 4: RT-PCR reaction system

[0100] composition volume Final concentration 2×Mix 10μL / 10μM Primer(F) 0.5μL 0.25μM 10μM Primer(R) 0.5μL 0.25μM Enzyme-free water 4μL / Template DNA 5μL / Total 20μL /

[0101] Table 5: RT-PCR reaction procedure

[0102]

[0103] 5. Drawing of monoclonal cell growth curve:

[0104] The top five monoclonal cells with the highest number of BaEV-Rless and BaEV-WT envelope copies were selected, and 4 × 10 5 The cells were inoculated in six-well plates, and HEK293T cells were used as controls. The cells were counted every two days and the growth curve was drawn. Fig.10 ). The doubling time of all monoclonal cells was delayed compared with HEK293T. Among them, BaEV-WT-64 and BaEV-Rless-57 grew faster and were subsequently tested for their toxin production ability.

[0105] 6. Detection of the ability of monoclonal cell transient transfection to produce toxins:

[0106] The above-mentioned two monoclonal cells, BaEV-Rless-57 and BaEV-WT-64, were selected for transient transfection and toxin production tests. The two cells were inoculated into six-well plates respectively and transfected 24 hours later. Prepare the transfection system: the amount of pMFG-copGFP plasmid is 3.3μg, the ratio of Fugene HD: DNA is 3:1, and the DMEM medium is filled to 200μL. After mixing, let it stand at room temperature for 15 minutes, add 200μL to each well, and culture it in a 37℃, 5% CO2 incubator. After 24 hours of transfection, replace with fresh DMEM complete medium and place it in a 32℃ incubator for toxin production. After 48 hours, collect the cell supernatant, filter the cell culture supernatant with a 0.45μm filter membrane, and perform titer detection.

[0107] 7. Titer detection:

[0108] HEK293T cells were seeded in 24-well plates at 2 × 10 5 cells. After 24 hours, discard the cell culture medium, add 1mL of the virus to be tested, then add 1μg / mL of polybrene, and centrifuge at 32℃2500rpm for 1h. Place in a 37℃ incubator and continue to culture. After 24 hours of viral transduction, replace with fresh culture medium. After 48 hours, flow cytometry is used to detect the GFP positive rate to calculate the transduction efficiency ( Fig.11 ), flow cytometry was used to detect the infection positive rate of retrovirus produced by BaEV-Rless-57 and BaEV-WT-64 monoclonal cells transiently transfected with pMFG-copGFP in HEK293T cells, which reflects the biological titer of the virus. Virus titer calculation method: virus titer (TU / mL) = number of cells infected × percentage of positive cells / volume of virus stock solution (Table VI).

[0109] No syncytia were found in BaEV-WT-64 and BaEV-Rless-57 cells during transient virus production. According to the virus production titer test, the virus titer packaged by BaEV-WT-64 was higher than that of BaEV-Rless-57, and the stable virus production test was performed later.

[0110] Table 6: Results of transient transfection titer detection of BaEV-Rless-57 and BaEV-WT-64

[0111] Positive rate Titer (TU / mL) BaEV-Rless-57 9.52% 3.8e5 BaEV-WT-64 21.8% 8.72e5

[0112] Example 4 Construction of BaEV-copGFP Retroviral Vector Packaging Cell Line

[0113] 1. Preparation of BaEV-copGFP retroviral vector:

[0114] The pMFG-copGFP plasmid is used to produce viruses that express copGFP and is used to test the WT and Rless envelopes. A two-step approach was adopted to construct BaEV-Rless-copGFP and BaEV-WT-copGFP virus-producing cell lines, using Phoenix-Ampho and BaEV-Rless / BaEV-WT retroviral vector packaging cell lines in turn. The pMFG-copGFP plasmid was transfected into Phoenix-Ampho cells and the cell supernatant was collected to harvest the ecotropic retroviral vector. It was mixed with BaEV-Rless / BaEV-WT cells and horizontal centrifugation was used to promote the transduction of retroviral vectors into BaEV cells to obtain a stable BaEV retroviral vector packaging cell line. The transduction positive rate of BaEV-Rless-copGFP cells and BaEV-WT-copGFP cells was detected by flow cytometry, and the transduction positive rate of both cells reached 60% ( Fig.12 ), and virus preparation can be performed subsequently.

[0115] 2. Preparation and titer detection of BaEV-copGFP retroviral vector:

[0116] BaEV-Rless-57-copGFP cells and BaEV-WT-64-copGFP cells were expanded to T75 culture flasks and placed in a 32°C incubator for toxin production. After 48 hours, the cell culture supernatants were collected and filtered through a 0.45 μm filter membrane for titer detection ( Fig.13 ), flow cytometry was used to detect the infection positive rate of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP stably produced retroviruses in HEK293T cells, reflecting the biological titer of the virus. Virus titer calculation method: virus titer (TU / mL) = number of cells infected × percentage of positive cells / volume of virus stock solution (Table VII). The transient and stable virus titers of BaEV-WT-64 cells were higher than those of BaEV-Rless-57, and BaEV-WT-64 was subsequently selected as the BaEV retroviral vector packaging cell line (BaEV-PackRV).

[0117] Table 7: Results of the detection of stable toxin production titers of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP

[0118] Positive rate Titer (TU / mL) BaEV-Rless-57-copGFP 2.42% 9.68e5 BaEV-WT-64-copGFP 17.7% 1.4e6

[0119] Example 5 Transient transfection of pMFG-CD19 CAR plasmid to prepare retroviral vector

[0120] In this example, the retroviral vector prepared by transient transfection with the pMFG-CD19 CAR plasmid was used and the cell supernatant was collected to investigate the transfection efficiency of Phoenix-Ampho cells at different harvest times and the biological titer of the retroviral vector. The specific process is as follows.

[0121] 1. Recovery and culture of Phoenix-Ampho cells

[0122] Take out the frozen Phoenix-Ampho adherent cells from the liquid nitrogen tank, thaw quickly in a 37°C water bath, centrifuge at 1000rpm / min for 5min, discard the supernatant, resuspend with an appropriate amount of DMEM complete medium containing 10% FBS (fetal bovine serum), transfer to T75, and culture in a 37°C, 5% carbon dioxide incubator until the monolayer is confluent for transfection.

[0123] 2. Transfection of Phoenix-Ampho cells with pMFG-CD19 CAR plasmid

[0124] 1. Inoculate Phoenix-Ampho cells in a 6-well cell culture plate at a density of 5 × 10 5 / well, placed in a 37°C, 5% carbon dioxide incubator for cell culture;

[0125] 2. After culturing cells for ~24 hours, when the confluence of Phoenix-Ampho cells reaches 80-90%, transfection experiments are performed;

[0126] 3. Take out the 6-well cell culture plate inoculated with Phoenix-Ampho cells from the carbon dioxide incubator, remove the old culture medium in the culture plate, and replace it with fresh DMEM complete culture medium containing 10% fetal bovine serum;

[0127] 4. Prepare transfection complex: According to the instructions of the transfection reagent, take an appropriate volume of transfection reagent FuGene HD and mix with pMFG-CD19 CAR retroviral vector plasmid, incubate for ~10 minutes, and obtain transfection complex;

[0128] 5. Transfection: The transfection complex obtained above was added dropwise to the 6-well cell culture plate containing Phoenix-Ampho cells, and ~0.2 mL of the transfection complex was added to each well. After mixing, the 6-well cell culture plate was placed in a 37°C, 5% carbon dioxide incubator for static culture;

[0129] 6. Change medium culture: 24 hours after transfection, take out the 6-well cell culture plate from the incubator, remove the old culture medium in the culture plate, replace it with fresh DMEM complete culture medium containing 10% fetal bovine serum (replacement volume: 2.5 mL / well), and then place the culture plate in a 37°C, 5% carbon dioxide incubator for continued culture.

[0130] Investigation on the optimal harvesting time of transient retrovirus: The design is shown in Table 8. After the culture plate is placed in a 37°C, 5% carbon dioxide incubator for continued culture for different periods of time, the cell culture supernatant and Phoenix-Ampho cells in the 6-well plate are harvested at the above different time points to obtain a transient retrovirus vector carrying the CD19 CAR exogenous gene.

[0131] After the pMFG-CD19 CAR plasmid was used to transfect Phoenix-Ampho cells, the specific myc tag in the plasmid was expressed on the surface of Phoenix-Ampho cells, and anti-hc-Myc flow cytometry antibody was used to detect the transfection efficiency (transfection positive rate) of the pMFG-CD19 CAR plasmid transfected Phoenix-Ampho cells. The results are shown in Table 9.

[0132] Detection of biological titer of transient transfected retrovirus: 293-T cells were inoculated into 24-well plates, and the number of transduced cells was 5×105 / well. The retroviral supernatant after transient transfection was diluted 5 times and then infected with 293-T cells, with a virus volume of 500uL / well, and polybrene was added as a transfer agent. Two days after infection, the infected 293-T cells were collected and the positive rate of 293-T cells was detected by flow cytometry. The biological titer was calculated as follows: Titer (TU / mL) = number of transduced cells × positive rate × dilution factor ÷ virus volume. The results are shown in Table 10.

[0133] Table 8: Time points for harvesting transient retroviral vectors after medium replacement

[0134] Group 1 2 3 4 5 6 7 8 Virus harvest time / (h) 8 16 24 48 72 96 120 148

[0135] Table 9: Results of harvesting transient retroviral vectors after culture medium replacement

[0136]

[0137] Table 10: Biological titer detection of retrovirus harvested at different times after transient transfection

[0138]

[0139]

[0140] According to the transfection positive rate in Table 9 and the biological titer experimental results in Table 10, when the pMFG-CD19CAR plasmid was transfected into Phoenix-Ampho cells and the viral vectors were harvested 8h and 16h after the medium was changed, the transfection positive rate of Phoenix-Ampho cells was less than 20%, indicating that the positive cells did not proliferate in a short period of time, and the biological titer of the transient retroviral vector was low and could not meet the subsequent generation requirements. 24h after culture medium change, the positive transfection rate of Phoenix-Ampho cells increased significantly to 67.3%. Continuous culture found that 48h, 72h, and 96h after culture medium change, the positive transfection rate of Phoenix-Ampho cells was higher than 85%, and reached a maximum of 95.5% at 96h. The cell viability was higher than 90%. The biological titer gradually increased with the increase of culture time, reaching a maximum of 9.95E+05TU / mL at 96h, indicating that the positive transfection rate of Phoenix-Ampho cells was the highest during this time. The pMFG-CD19CAR gene was highly expressed in Phoenix-Ampho cells, and high-titer transient retroviral vectors could be harvested. As the time for harvesting viral vectors increased, the cell transfection positive rate decreased after culture medium replacement and culture for 120h and 148h. This may be because the proliferation rate of non-transfected Phoenix-Ampho cells exceeded that of transfected Phoenix-Ampho cells, and the transfected cells gradually died. The biological titer gradually decreased, indicating that a longer culture time may not be conducive to the harvest of high-titer retroviral vectors.

[0141] Based on all the results of this example, we believe that the optimal time for harvesting viral vectors after transfection and culture is 48 to 96 hours, at which time the Phoenix-Ampho cell transfection positive rate is higher than 90%, and the cell viability is higher than 90%, and the biological titer is high. The transient CD19 CAR retroviral vector harvested during this period can be used for subsequent cell transduction.

[0142] Example 6 Transduction of BAEV-PackRV cells with CD19 CAR retroviral vector harvested from transient transfection

[0143] In this example, the CD19 CAR retroviral vector harvested by transient transfection in Example 5 was used to transduce BAEV-PackRV cells, and the effects of different combinations of virus centrifugation temperature, centrifugation time, and cell incubation time after centrifugation on the transduction efficiency of BAEV-PackRV cells were investigated. The process is as follows.

[0144] 1. Recovery culture of BAEV-PackRV cells: Take out the frozen BAEV-PackRV adherent cells from the liquid nitrogen tank, thaw quickly in a 37°C water bath, centrifuge at 1000rpm / min for 5min, discard the supernatant, resuspend the cell pellet with an appropriate amount of DMEM complete medium containing 10% fetal bovine serum, transfer it to a T75 cell culture flask, place it in a 37°C, 5% carbon dioxide incubator and culture it statically until the cells grow a full monolayer for transduction.

[0145] 2. Transduction of BAEV-PackRV cells with CD19 CAR transient retroviral vector

[0146] 1. Transduction reagent coating: Use RetroNectin to promote transduction reagent coating of 12-well plates, that is, dilute RetroNectin to 20ug / mL, add 1mL to each well of the 12-well plate, and store in a 2-8℃ refrigerator.

[0147] 2. Transient retroviral vector centrifugation enrichment: After 24 hours, take out the 12-well plate from the 2-8°C refrigerator, aspirate the RetroNectin coating solution in the well plate, add 1 mL of the transient CD19CAR retroviral vector prepared in Example 5 to the 12-well plate, centrifuge at 2000rpm for 1 hour, enrich the CD19 CAR retroviral vector in the 12-well plate, and then discard the unenriched retroviral vector to obtain a 12-well plate enriched with the CD19CAR retroviral vector for standby use.

[0148] 3. Preparation of transduced cells: Take out BAEV-PackRV cells from the 37°C, 5% carbon dioxide incubator, add trypsin to digest the cells, and terminate the digestion with DMEM complete medium containing 10% fetal bovine serum. Count the cells and take 1×10 5 BAEV-PackRV cells were centrifuged to obtain cell pellets for later use.

[0149] 4. One-time centrifugal transduction: Take 1 mL of transient CD19 CAR retroviral vector, resuspend the transduced BAEV-PackRV cells prepared above, mix the viral vector and BAEV-PackRV cells, and put them into the 12-well plate that has been enriched with CD19CAR retroviral vector in the above "2", and then centrifuge at different temperatures for different times, and the BAEV-PackRV cells obtained by centrifugation are placed in a 37°C, 5% carbon dioxide incubator for different periods of time to investigate the effects of different centrifugation temperatures, centrifugation times and incubation time combinations on BAEV-PackRV cell transduction. The specific experimental design is shown in Table 11 below.

[0150] 5. Non-centrifugation control group: Take 1 mL of transiently transfected CD19 CAR retroviral vector, resuspend the BAEV-PackRV cells in the above "3", mix the viral vector and BAEV-PackRV cells, put them into the 12-well plate enriched with CD19 CAR retroviral vector in the above "2", and incubate them in a 37°C, 5% carbon dioxide incubator for 24 hours.

[0151] Table 11: Experimental design of CD19 CAR transient viral vector transduction into BAEV-PackRV cells

[0152]

[0153]

[0154] According to the above Table 11, a centrifugal transduction experiment was performed in groups. After the experiment, the CD19CAR transient retroviral vector in each group of 12-well plates was discarded, and fresh DMEM complete medium containing 10% fetal bovine serum was added, and placed in a 37°C, 5% carbon dioxide incubator for static culture. After 48 hours, the BAEV-PackRV cells in each group of wells were digested with trypsin, and the cell viability and transduction positive rate were detected after centrifugation. Because the specific myc tag will be expressed on the surface of the transduced BAEV-PackRV cells, the anti-hc-Myc flow cytometry antibody was used to detect the transduction positive rate and cell viability of the CD19 CAR transient retroviral vector transduced BAEV-PackRV cells. The results are shown in Table 12 below.

[0155] Table 12 Effects of different centrifugation and incubation conditions on CD19 CAR transient retroviral vector transduction into BAEV-PackRV cells

[0156]

[0157]

[0158] Results analysis: By comparing the test results of the experimental centrifugation groups 1-27 and the control non-centrifugation group 28, when the cells were incubated and cultured by centrifugation at 4°C, the cell viability of the experimental groups 1-9 was lower than 90%, and the positive rate was lower than 10%, indicating that low temperature conditions would lead to a decrease in cell viability and a large number of transduced cells died; when the cells were incubated and cultured by centrifugation for 0.5h, the cell viability of the experimental groups 10-13, 16, 19-22, and 25 was higher than 90%, but the positive rate was lower than 20%, indicating that the short centrifugation time and incubation time during transduction were not conducive to transduction; the control group 28 had a low transduction efficiency, indicating that non-centrifugation could not promote transduction. According to the results in Table 12, the cell viability of the experimental groups 14, 15, 17, 18, 23, 24, 26 and 27 was higher than 90%, and the positive rate was higher than 20%, but the transduction positive rate could not reach more than 90%, which could not meet the requirements of subsequent high-titer viral vector harvesting.

[0159] In order to further improve the transduction positive rate of BAEV-PackRV cells, we tried to increase the number of centrifugal transductions and investigate the transduction effects of different centrifugal times, centrifugal temperatures, centrifugal times, and post-centrifugal incubation times on the transduction positive rate of BAEV-PackRV cells transduced with CD19 CAR transient retroviral vectors. The operation was performed as follows:

[0160] 1. Transduction reagent coating: Use RetroNectin to promote transduction reagent coating of 12-well plate, that is, dilute RetroNectin to 20ug / mL, add 1mL to each well of 12-well plate, and store in a refrigerator at 2-8℃;

[0161] 2. Transient retroviral vector centrifugation enrichment: After 24 hours, take out the 12-well plate from the 2-8°C refrigerator, aspirate the RetroNectin coating solution in the well plate, add 1 mL of the transient CD19CAR retroviral vector prepared in Example 1 to the 12-well plate, centrifuge at 2000 rpm for 1 hour, enrich the CD19 CAR retroviral vector in the 12-well plate, and then discard the unenriched retroviral vector to obtain a 12-well plate enriched with CD19CAR retroviral vector for standby use;

[0162] 3. Preparation of transduced cells: BAEV-PackRV cells

[0022] were taken out of the 37°C, 5% carbon dioxide incubator, and trypsin was added to digest the cells. The digestion was terminated with DMEM complete medium containing 10% fetal bovine serum, and the cells were counted. 1×10 5 BAEV-PackRV cells were centrifuged to obtain cell pellets for later use;

[0163] 4. One-time centrifugal transduction: Take 1 mL of transient CD19 CAR retroviral vector, resuspend the BAEV-PackRV cells in step 3, mix the viral vector and BAEV-PackRV cells, and place them in the 12-well plate that has been enriched with CD19 CAR retroviral vector in step 2 to investigate the effects of different centrifugation temperatures, centrifugation times and incubation time combinations on BAEV-PackRV cell transduction. The specific design is shown in Table 13 below.

[0164] 5. Secondary centrifugal transduction: After the first centrifugal transduction and incubation in step 4, the 12-well plate was taken out from the 37°C, 5% carbon dioxide incubator, the viral vector supernatant in the well plate was discarded, and 1 mL of fresh transient CD19 CAR retroviral vector was added to investigate the effects of different centrifugation temperatures, centrifugation times, and incubation time combinations on BAEV-PackRV cell transduction. The specific design is shown in Table 13 below.

[0165] Table 13 Experimental design of multiple transductions of BAEV-PackRV cells with CD19 CAR transient viral vector According to the above Table 13, the centrifugal transduction experiment was performed in groups. After the experiment, the CD19CAR transient retroviral vector in each group of 12-well plates was discarded, and fresh DMEM complete medium containing 10% fetal bovine serum was added, and placed in a 37°C, 5% carbon dioxide incubator for static culture. After 48 hours, the BAEV-PackRV cells in each group of wells were digested with trypsin, and the transduction positive rate and cell viability of the CD19 CAR transient retroviral vector transduced BAEV-PackRV cells were detected using anti-hc-Myc flow cytometry antibodies. The results are shown in Table 14 below.

[0166] Table 14 Effects of different centrifugation and incubation times on the transduction of BAEV-PackRV cells with CD19 CAR transient retroviral vectors

[0167]

[0168]

[0169] According to the experimental results in Table 14, the transduction efficiency and cell viability test results of two centrifugal transductions and one centrifugal transduction were analyzed, and it was found that under the conditions of 32°C and 37°C, the viability of the transduced BAEV-PackRV cells was higher than 90%, but the positive rate of the experimental group 1-8 transduced twice (more than 70%) was much higher than the positive rate of the control group 9-16 transduced once (25-30%), indicating that the present invention can effectively improve the transduction positive rate of BAEV-PackRV cells by increasing the number of centrifugation times during transduction. However, the centrifugation temperature during transduction of the experimental group 5-8 was 37°C, and the transduction positive rate was about 70-80%, which was significantly lower than the transduction positive rate of the experimental group 1-4 of more than 90%, indicating that centrifugation at 32°C can significantly promote BAEV-PackRV cell transduction. Subsequently, by comparing the test results of the two centrifugal transductions of the experimental group 1-4, it was found that there was no significant difference in the cell positive rate after centrifugation for 1h, 2h and incubation for 2h, 3h.

[0170] Transduced cell expansion: The BAEV-PackRV cells of experimental groups 1-4 in Table 14 (with a higher transduction positive rate) were divided into T75 cell culture flasks at a ratio of 1:4 for subculture, subcultured once every 3 days, and cultured for 5 generations; samples were taken at each generation to detect cell viability and positive rate, and the results are shown in Table 15 below.

[0171] Table 15 Cell subculture results

[0172] Cultivation time (d) 3 6 9 12 15 Cell viability% 95.21 93.55 97.29 94.10 93.47 Transduction positive rate % 96.1 94.2 92.7 93.3 91.9

[0173] The above test results of the transduction efficiency and cell viability of BAEV-PackRV cells transduced with CD19CAR transient retroviral vectors using different combinations of centrifugation times, centrifugation temperatures, centrifugation times and incubation times showed that: two transductions, a transduction temperature of 32°C, a single centrifugation transduction time of 1 to 2 hours, and an incubation time of 2 to 3 hours after transduction can achieve efficient transduction of BAEV-PackRV cells with transient retroviral vectors, and the transduced cells can maintain a high viability and a stable positive rate after passage and amplification.

[0174] Example 7 Construction of BaEV-CD19 CAR and GALV-CD19 CAR Toxin-producing Cell Lines and Virus Preparation

[0175] 1. Construction of BaEV-CD19 CAR toxin-producing cell line

[0176] As described in Example 6, the retroviral vector is promoted to transduce the BaEV stable packaging cell line by horizontal centrifugation to obtain a stable BaEV-CD19 CAR retroviral vector packaging cell line. After the cells are expanded and cultured, the cell culture supernatant is collected to obtain the retroviral vector for subsequent transduction of immune effector cells.

[0177] As described in CN117467706A, the term "chimeric antigen receptor" or "CAR" refers to a group of engineered polypeptides or proteins that, when in immune effector cells, bind to specific antigens contained on target cells and generate intracellular signals after recognizing the specific antigens, activating the downstream pathways of the cells where the receptors are located to initiate the killing of the target cells by the immune effector cells. The immune effector cells include, but are not limited to, NK cells, macrophages, neutrophils, T cells, and the like.

[0178] 2. Construction of GALV-CD19 CAR toxin-producing cell line

[0179] Phoenix-ECO and PG13 retroviral vector packaging cell lines were used in turn according to the method of "Construction of BaEV retroviral vector packaging cell line" above. Phoenix-ECO cells were transfected with pMFG-CD19 CAR plasmid and the cell supernatant was collected to harvest the ecotropic retroviral vector. It was mixed with PG13 cells and horizontal centrifugation was used to promote the transduction of retroviral vectors into PG13 cells to obtain a stable GALV-CD19 CAR retroviral vector packaging cell line. Cells were expanded and virus preparation was performed.

[0180] Example 8 BaEV-CD19 CAR, GALV-CD19 CAR transduction T cell test

[0181] 1. Plate coating: Add RetroNectin (10 μg / mL) to a 12-well plate (without tissue treatment), 1 mL per well. Incubate at 4°C in the dark overnight.

[0182] 2. Transduction: The next day, remove the RetroNectin solution and rinse with PBS. Use culture medium to dilute the viral vector to prepare the stock solution, two-fold and four-fold diluted viral vector suspensions, which are recorded as stock solution, 1:2 dilution and 1:4 dilution groups, respectively. Add 1 mL of the above BaEV-CD19 CAR retroviral vector and 1 mL of GALV-CD19 CAR retroviral vector to the coated 12-well plate, place in a 32°C centrifuge, centrifuge at 2500 rpm for 1 hour, and remove the viral supernatant in the well plate. Take 4×10 5After resuspending the activated T cells with 1 mL of BaEV-CD19 CAR retroviral vector or 1 mL of GALV-CD19 CAR retroviral vector, the cell suspension was added to the corresponding wells and polybrene (final concentration 6 μg / mL) was added. The 12-well plate was centrifuged at 2500 rpm for 1 hour at 32°C and then placed in a 37°C incubator for 2 hours. The supernatant in the well plate was discarded, the corresponding retroviral vector (containing polybrene) was added, and the well plate was placed in a 32°C centrifuge and centrifuged at 2500 rpm for 1 hour. After the end, the cells were placed in a 37°C incubator and incubated for 2 hours.

[0183] 3. Culture: Discard the supernatant in the well plate, add 1 mL of fresh T cell complete culture medium to resuspend the cells, add h-IL2 (final concentration 500 U / mL), and continue to culture.

[0184] 4. Transduction positive rate detection: 48 hours after transduction, take 2×10 5 After the transduced T cells were incubated with FITC-CD19-FC antigen at 4°C for 30 min, the transduction efficiency of T cells was detected by flow cytometry. Fig.14 ), flow cytometry was used to detect the positive rate of T cell transduction by two retroviruses, GALV-CD19 CAR and BaEV-CD19 CAR, according to the original solution, 1:2 dilution, and 1:4 dilution. When the titer of BaEV-CD19 CAR virus was lower than that of GALV-CD19 CAR virus, the positive rate of T cell transduction was significantly higher than that of GALV-CD19CAR. After the virus was diluted to 4 times, the positive rate of T cell transduction by BaEV-CD19 CAR virus at a lower MOI could maintain the same level as the original solution.

[0185] Each passage took 2 × 10 5 After the transduced CAR-T cells were incubated with FITC-CD19-FC antigen or G4S antibody at 4°C for 30 minutes, the transduction efficiency of T cells was detected by flow cytometry until 8 days after transduction. The CAR positive rate of CAR-T cells remained at the same level as the second day after transduction. The results of the positive rate of GALV-CD19 CAR and BaEV-CD19 CAR transduced T cells are shown in Table 16.

[0186] Table 16 Positive rate of GALV-CD19 CAR and BaEV-CD19 CAR transduced T cells

[0187]

[0188] 5. Amplification multiple detection: After transduction, the proliferation of CAR-T cells was continuously detected until the 8th day after transduction. There was almost no difference in the proliferation multiple of CAR-T cells transduced with BAEV-CD19-CAR at different dilution multiples and GaLV-CD19-CAR at different dilution multiples. Fig.15 As shown, it shows that BaEV envelope greatly improves the transduction efficiency of retroviral vectors to primary T cells while not affecting the normal proliferation of CAR-T cells.

[0189] Example 9 BaEV-CD19 CAR, GALV-CD19 CAR transduction NK cell test

[0190] 1. Plate coating: Add RetroNectin (10 μg / mL) to a 12-well plate (without tissue treatment), 1 mL per well. Incubate at 4°C in the dark overnight.

[0191] 2. Transduction: The next day, remove the RetroNectin solution and rinse with PBS. Use culture medium to dilute the viral vector to prepare the stock solution, two-fold and four-fold diluted viral vector suspensions, which are recorded as stock solution, 1:2 dilution and 1:4 dilution groups, respectively. Add 1 mL of the above BaEV-CD19 CAR retroviral vector and 1 mL of GALV-CD19 CAR retroviral vector to the coated 12-well plate, place in a 32°C centrifuge, centrifuge at 2500 rpm for 1 hour, and remove the viral supernatant in the well plate. Take 4×10 5 After resuspending the activated NK cells with 1 mL of BaEV-CD19 CAR retroviral vector or 1 mL of GALV-CD19 CAR retroviral vector, the cell suspension was added to the corresponding wells and polybrene (final concentration 6 μg / mL) was added. The 12-well plate was centrifuged at 2500 rpm for 1 hour at 32°C and then placed in a 37°C incubator for 2 hours. The supernatant in the well plate was discarded, the corresponding retroviral vector (containing polybrene) was added, and the well plate was placed in a 32°C centrifuge and centrifuged at 2500 rpm for 1 hour. After the end, the cells were placed in a 37°C incubator and incubated for 2 hours.

[0192] 3. Culture: Discard the supernatant in the well plate, add 1 mL of fresh NK cell complete culture medium to resuspend the cells, and continue to culture.

[0193] 4. Transduction positive rate detection: 48 hours after transduction, take 2×10 5 After the transduced NK cells were incubated with FITC-CD19-FC antigen at 4°C for 30 min, the transduction efficiency of NK cells was detected by flow cytometry. Fig.16), flow cytometry was used to detect the positive rate of NK cell transduction by two retroviruses, GALV-CD19CAR and BaEV-CD19 CAR, according to the original solution, 1:2 dilution, and 1:4 dilution. When the titer of BaEV-CD19 CAR was one-fold lower than that of GALV-CD19 CAR, the positive rate of BaEV-CD19 CAR transducing NK cells was GALV-CD19 CAR, and after the virus was diluted 4 times, the transduction positive rate remained stable at more than 90%. However, GALV-CD19 CAR only had a 20% transduction positive rate. In contrast, the BaEV envelope greatly improved the transduction efficiency of retroviral vectors to primary NK cells.

[0194] Each passage took 2 × 10 5 After the transduced NK cells were incubated with FITC-CD19-FC antigen at 4°C for 30 minutes, the transduction efficiency of NK cells was detected by flow cytometry. On the 22nd day after transduction, the CAR positive rate of CAR-NK transduced with BaEV envelope remained at the same level as the second day after transduction. The results of the positive rate of NK cells transduced with GALV-CD19 CAR and BaEV-CD19 CAR are shown in Table 17.

[0195] Table 17: Positive rate of NK cells transduced by GALV-CD19 CAR and BaEV-CD19 CAR

[0196]

[0197] 5. Amplification multiple detection: After transduction, the proliferation of CAR-NK was continuously detected until the 22nd day after transduction. There was almost no difference in the proliferation multiple of CAR-NK after transduction with BAEV-CD19 CAR of different dilution multiples and GaLV-CD19 CAR of different dilution multiples. Fig.17 As shown, it indicates that BaEV envelope greatly improves the transduction efficiency of retroviral vectors to primary NK cells while not affecting the normal proliferation of CAR-NK cells.

[0198] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.

Claims

1. A method for packaging a BaEV retroviral vector, the method comprising the following steps: Step 1: Construction of BaEV retrovirus stable packaging cell line; Step 2: transfecting a retroviral vector plasmid containing a target sequence into a virus production cell line, wherein the virus production cell line is a HEK293T cell line or a cell line derived therefrom, to harvest a transiently transfected retroviral vector; Step 3: The retroviral vector obtained in step 2 is mixed with the BaEV retroviral stable packaging cell line obtained in step 1, and horizontal centrifugation is performed to promote the retroviral vector to transduce the BaEV retroviral stable packaging cell line.

2. The packaging method according to claim 1, characterized in that: Step 1 includes the following steps: Step 11: Transform the structural protein gag-pol protein required for the preparation of retrovirus into HEK293T cell line or its derivative cell line to obtain the corresponding cell line containing the structural protein gag-pol protein; Step 12: Based on the cell line obtained in step 11, a HEK293T cell line or a cell line derived therefrom in which both ASCT-1 and ASCT-2 receptor proteins are knocked out is constructed to obtain a cell line in which both ASCT-1 and ASCT-2 receptor proteins are knocked out accordingly; Step 13: Transfer the BaEV envelope into the cell line obtained in step 12 to obtain the BaEV retrovirus stable packaging cell line.

3. The method according to claim 2, characterized in that The step 11 comprises: Step 111, transfecting HEK293T cell line or its derivative cell line with gag-pol plasmid; Step 112, after transfection, adding antibiotics to screen HEK293T cell lines or cell lines derived therefrom that highly express the gag-pol target gene; Step 113, digesting the HEK293T cell line or its derivative cell line obtained in step 112, culturing the digested cells, and selecting monoclonal cells; Step 114, performing transient toxin production titer test on the monoclonal cells obtained in step 113, screening monoclonal cells with high toxin production titer, and obtaining the corresponding cell line containing the structural protein gag-pol protein.

4. The method according to claim 2, characterized in that: The step 12 comprises: Step 121, knocking out the ASCT-1 gene in the cells containing the structural protein gag-pol protein obtained in step 11; Step 122, flow sorting and culturing the cells obtained in step 121 to obtain monoclonal cells; Step 123, selecting the monoclonal cells obtained in step 122, performing a targeting test, and obtaining monoclonal cells homozygous for ASCT-1 gene knockout; Step 124, knocking out two exons of the ASCT-2 gene in the monoclonal cells obtained in step 123, and further selecting the monoclonal cells to obtain cells in which the ASCT-1 and ASCT-2 receptor proteins are knocked out.

5. The method according to claim 2, characterized in that: The step 13 comprises: Step 131, transfecting the ASCT-1 and ASCT-2 receptor protein knockout cells obtained in step 12 with BaEV envelope plasmid; Step 132, after transfection, adding antibiotics to screen for retroviral vector packaging cell lines that highly express the BaEV envelope; Step 133, digesting the BaEV enveloped retroviral vector packaging cell line obtained in step 132, culturing the digested cells, and selecting monoclonal cells; Step 134, performing a transient toxin production titer test on the monoclonal cells obtained in step 133, screening monoclonal cells with high toxin production titers, and obtaining the BaEV retrovirus stable packaging cell line.

6. The method according to claim 5, characterized in that In step 131, the BaEV envelope plasmid is a wild-type BaEV envelope plasmid or a BaEV-Rless envelope plasmid.

7. The packaging method according to claim 1, characterized in that: The reverse transcription vector plasmid including the target sequence in step 2 is pMFG-CD19 CAR plasmid, and the virus preparation cells in step 2 are Phoenix-Ampho cells.

8. The packaging method according to claim 7, characterized in that: When the pMFG-CD19 CAR plasmid is transfected into the Phoenix-Ampho cells and the transfected Phoenix-Ampho cells are cultured in a medium-changing manner for 48-96 hours, the cell culture supernatant and Phoenix-Ampho cells are harvested to harvest the transiently transfected toxin-producing retroviral vector of step 2.

9. The packaging method according to claim 8, characterized in that: In step 3, when horizontal centrifugation is used to promote the transduction of the retroviral vector into the BaEV retroviral stable packaging cell line, the retroviral vector obtained in step 2 is first mixed with the BaEV retroviral stable packaging cell line obtained in step 1 for the first centrifugal transduction and incubation to obtain the first transduced BaEV retroviral stable packaging cell line; then the retroviral vector obtained in step 2 and the first transduced BaEV retroviral stable packaging cell line are subjected to a second centrifugal transduction and incubation to finally obtain the BaEV retroviral stable packaging cell line in step 3.

10. The packaging method according to claim 9, characterized in that: The temperature of the first centrifugal transduction or the second centrifugal transduction is 32° C., the centrifugal transduction time is 1 to 2 hours, and the post-transduction incubation time is 2 to 3 hours.

11. A BaEV retrovirus stable packaging cell line prepared according to the packaging method according to any one of claims 1-10.

Citation Information

Patent Citations

  • Lentiviral vectors pseudotyped with mutant BaEV glycoproteins

    CN104080917A

  • Efficient BaEV envelope virus packaging method

    CN117467705A

  • Lipid particles containing truncated baboon endogenous retroviral (BaEV) envelope glycoproteins and related methods and uses

    CN117642420A

  • Engineering of gamma delta T cells and compositions thereof

    CN117795083A

  • Modified virus vector, lentivirus and application

    CN117820444A

Cited By

  • Batch production method of retroviral vector, and vector and application thereof

    CN119020417A